The debate over the SERENA-6 trial centers not on drug efficacy, but on its unique design. Intervening at molecular relapse (ESR1 mutation) instead of clinical progression creates a new patient population that doesn't fit neatly into first-line maintenance or second-line treatment categories. This ambiguity complicates regulatory interpretation and defining the appropriate control arm.

The SERENA-6 trial showed improved survival by switching therapy upon ctDNA detection of ESR1 mutations. However, it required screening over 3,300 patients to randomize just 315, highlighting the immense scale, cost, and patient drop-off of applying this serial monitoring strategy in standard clinical practice.

The SERENA-6 strategy of switching to an oral SERD upon detecting an ESR1 mutation in ctDNA—before clinical progression—is a novel concept. It forces oncologists to grapple with the idea of 'molecular progression' and whether this biomarker-led switch truly alters the disease's natural history.

ODAC's critique of the SERENA-6 trial, focusing on immature overall survival (OS) data, contrasts sharply with previous landmark approvals like CDK4/6 inhibitors, which were approved without OS data. This suggests innovative, biomarker-adaptive trials may face a higher, potentially unfair, regulatory bar.

Despite showing a progression-free survival (PFS) benefit, oncologists advise against the SERENA-6 strategy of switching therapy upon detecting an ESR1 mutation before clinical progression. The lack of overall survival data, flawed trial comparison (PFS vs PFS2), and significant cost burdens make this approach premature for clinical practice.

The SERINA-6 trial suggests a paradigm shift: proactively switching from an AI to an oral SERD upon detecting an ESR1 mutation in ctDNA—before clinical or radiographic progression—significantly improves progression-free survival and patient quality of life.

SERENNA-six pioneers a strategy where treatment is switched upon detecting an ESR1 resistance mutation in ctDNA, *before* the patient shows clinical signs of progression. This proactive, biomarker-driven approach represents a paradigm shift from reactive treatment of progressing disease.

Despite the promise of liquid biopsies for monitoring, the SERENA-6 trial revealed a significant challenge: fewer than 10% of screened patients developed a detectable ESR1 mutation. This low yield questions the efficiency and broad applicability of this serial screening strategy to guide treatment changes.

The SERINA-6 trial supports a paradigm shift: proactively screening for ESR1 mutations via blood test and switching to camisestrant upon detection, even without radiological progression. This early switch based on molecular signals nearly doubled median progression-free survival from 9 to 16 months.